A study known as the REDUCE trial suggests that the addition of spironolactone, a widely used diuretic, could help manage elevated blood pressure in stroke survivors when traditional treatments fall short. This research was presented at the American Heart Association’s Scientific Sessions held in Chicago from November 6 to 9, 2026.
Study Methodology
The trial involved splitting participants into two groups. One group incorporated spironolactone into their regular treatment regimen, while the other continued with the standard post-stroke care. Over six months, researchers tracked participants’ blood pressure at home to assess the impact of spironolactone addition.
Study Findings
After three months, those who took spironolactone showed an average reduction of nearly eight points in systolic blood pressure compared to the control group, with average readings of 126 and 133 respectively. Moreover, 52% of participants taking spironolactone reached the recommended blood pressure goal of less than 130/80, contrasted with 30% of those receiving usual care.
“Lowering blood pressure is critical in preventing recurrent strokes. But many survivors find it challenging to meet the recommended targets,” said Dr. Jordana Cohen, co-lead author and associate professor at the University of Pennsylvania.
Dr. Alfred Joshua, a board-certified emergency physician, commented on the findings. “We know that controlling blood pressure mitigates stroke risk. However, more research is needed to confirm if spironolactone actually reduces recurrent strokes,” he added.
How Spironolactone Works
The U.S. National Library of Medicine explains that spironolactone aids in expelling extra salt and water from the body, which contributes to lowering blood pressure. However, it also causes potassium retention, necessitating regular monitoring of potassium levels to avoid complications such as dizziness and elevated potassium, particularly in individuals with kidney issues or those taking potassium supplements.
Dr. Joshua advised, “If you’re dealing with high blood pressure after a stroke, consult with your healthcare provider about whether spironolactone could be beneficial.”
Study Limitations and Future Research
The trial concluded earlier than planned, involving 160 participants rather than the intended 200. Notably, blood pressure readings were unavailable for about 15% of participants at the three-month milestone. Additionally, participants on spironolactone were also on slightly more blood pressure medications than those adhering to usual care. The study was not designed to determine if spironolactone prevents recurrent strokes or heart attacks, necessitating larger and longer trials to explore this further.
For more detailed health insights, consider consulting the latest health news or signing up for newsletters focused on this subject.

The Future of MAHA in American Health Politics
Insulin Cost Caps Gaining Support Amid Rising Prices
Efforts to Counter Food Assistance Cutbacks in San Diego
A Personal Journey Through Encephalitis
The Complex Debate Over Kratom Use in the U.S.
Florida’s Struggle with Dengue Fever and AI Solutions